[ET Net News Agency, 25 May 2021] Daiwa raised its target price for Akeso (09926) to
HK$69.9 from HK$58.6 and maintained its "outperform" rating.
The research house said it is more conservative that the market on the out-licensing
outlook for penpulimab in the US market. (RC)